Administered for the stoppage of bleeding during surgical interference and different morbid conditions during which the fibrinolysic intensity of blood and tissues increases, after operation in lungs, prostate glands, gasteral glands and thyroid glands.
Aminocaproic acid (Aminocaproic acid)
Hemostatic agent, an inhibitor of fibrinolysis
granules for suspension for oral administration [for children], solution for infusion
Hemostatic agent, inhibits the conversion of plasminogen to fibrinolysin, apparently by inhibiting the activator of this process, as well as having a direct inhibitory effect on fibrinolysin; inhibits the activating effect of streptokinase, urokinase and tissue-kinase on fibrinolysis, neutralizes the effects of kallikrein, trypsin and hyaluronidase, reduces capillary permeability. Possesses anti-allergic activity, improves the antitoxic function of the liver.
Bleeding (hyperfibrinolysis, hypo-and afibrinogenemia), bleeding during surgery and pathological conditions involving increased blood fibrinolytic activity (in neurosurgical, intracavitary, thoracic, gynecological and urological surgery, including for prostate, lung, pancreas; tonsillectomy after dental procedures, for operations using artificial blood circulation apparatus). Internal diseases with hemorrhagic syndrome, premature separation of placenta, complications of abortion. Prevention of secondary hypofibrinogenaemia with massive transfusions of preserved blood.
Hypersensitivity, hypercoagulability (thrombosis, thromboembolism), the tendency to thrombosis and thromboembolic disease, cerebrovascular accidents, DIC, beremennost.C caution. Hypotension, valvular heart disease, hematuria, bleeding from the upper urinary tract of unknown etiology, liver failure, chronic renal failure.
Dizziness, tinnitus, headache, nausea, diarrhea, stuffy nose, skin rash, decreased blood pressure, orthostatic hypotension, muscle cramps, rhabdomyolysis, myoglobinuria, acute renal failure, subendocardial hemorrhage.
Dosage and administration:
In / in, drip. In acute bleeding, administered 4-5 g dissolved in 250 ml of 0.9% solution of NaCl, for 1 hour, then if necessary, 1 g (50 ml) every hour for 8 hours or until it stops bleeding. With continued bleeding infusion repeated every 4 hours, oral, 5 g, followed by 1 g every hour for no more than 8 hours to a full stop bleeding. Children, the rate of 100 mg / kg - 1 h, then 33 mg / kg / h, the maximum daily dose - 18 grams per square meter. Daily intake for adults - 5-30 g; for children under 1 year - 3 g; 2-6 years - 3-6 v 7-10 years - 6-9, the case of acute blood loss: children under 1 year - 6 g , 2-4 years - 6-9 g, 5-8 years - 9-12 g, 9-10 years - 18 g. Duration of treatment - 3-14 days.
Anticoagulants are the direct and indirect, reduce the effectiveness of antiplatelet agents